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Kathryn B. Garber1,*To Test or Not to Test, That Is Still the Question
Despite the fact that familial hypercholesterolemia (FH) is
believed to be one of the most common inherited diseases,
the majority of affected individuals go undetected and
their high cholesterol goes unmanaged (or at least under-
managed). Because of this, guidelines written by such
groups as the United Kingdom’s National Institute for
Clinical Health and Excellence recommend cascade testing
in families once an index case has been identified.
Although identification of the causative mutation makes
this somewhat more straightforward, the relevant muta-
tion cannot be detected in a substantial fraction of individ-
uals who meet the criteria for diagnosis of FH. A recent
analysis by Talmud et al. suggests that at least some of
these ‘‘mutation-negative’’ individuals might have FH in
a polygenic form of the disease. In their analysis, they
used genotype data from 12 SNP alleles previously associ-
ated with increased low-density-lipoprotein cholesterol
(LDL-C) to generate personalized LDL-C gene scores. A
group of FH-affected individuals in whom no single gene
cause could be detected had a significantly higher mean
weighted gene score than did a set of control individuals.
This suggestion of polygenic FH led the authors to ques-
tion the utility of cascade testing in mutation-negative
families because the lower predicted proportion of affected
family members reduces the cost effectiveness of this
strategy. An accompanying comment by Stein and Raal
argues for the value of cascade testing in FH no matter
the underlying cause.
Talmud et al. (2013). Lancet. Published online February 22,
2013. http://dx.doi.org/10.1016/S0140-6736(12)62127-8.
Stein and Raal (2013). Lancet. Published online February 22,
2013. http://dx.doi.org/10.1016/S0140-6736(13)60187-7.
Lumpers and Splitters
As with other diseases, when it comes to mental illness,
we tend to want to give a specific diagnosis to affected in-
dividuals. Modern diagnostic criteria reflect this and split
psychiatric illness into discrete categories, although they
might have overlapping features. Does that mean each
is the result of a separate biological process gone awry?
Perhaps not. A recent large genome-wide association
study from the Psychiatric Genetics Consortium indicates
that at least some psychiatric conditions might instead be
lumped together, at least in terms of their underlying
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The Ama set of individuals with schizophrenia, bipolar disorder,
major depressive disorder, autism, or attention-deficit
hyperactivity disorder and compared this combined case
group of more than 33,000 individuals to nearly 28,000
controls. Four SNPs reached genome-wide significance,
and two of these lay within genes for voltage-gated
calcium-channel subunits. A pathway analysis further
supported the role of calcium signaling channels in these
disorders. It has become clear over the past few years that
certain rare copy-number variants confer risk of more
than one psychiatric disorder. This study argues that there
can also be overlap in the common sequence variation
that underlies these disorders and that certain biological
pathways might be at the root of a range of neurodevelop-
mental disorders and mental illness.
Cross-Disorder Group of the Psychiatric Genetics Consortium
(2013). Lancet. Published online February 28, 2013. http://dx.
doi.org/10.1016/S0140-6736(12)62129-1.
Reflections on Incidental Findings
Most often when genetic testing is ordered, one is looking
for a genetic change that explains a certain health problem
that an affected individual is experiencing. As we begin to
use whole-exome and whole-genome sequencing, though,
we will commonly find additional sequence changes that
might have some clinical significance. These so-called
‘‘incidental findings’’ are a subject of much recent interest
in the literature. Whereas Clayton and colleagues explore
legal precedent surrounding incidental medical findings
and discuss the implications for reporting the results of
genetic testing, Christenhusz et al. perform a systematic
review of ethical reasons for and against the disclosure of
incidental findings from genetic testing. Although geneti-
cists have hemmed and hawed about the extent to which
incidental findings should be disclosed and in which
scenarios, Facio et al went straight to the source (of the
DNA samples, that is) and collected attitudes and inten-
tions towards receiving genetic test results in participants
of the National Institutes of Health ClinSeq study. Their
participants indicated a strong preference for receiving
information about their genomes, whether or not it was
currently interpretable or actionable. These ethical, legal,
and social aspects of returning incidental findings to
affected individuals and research participants need to be
balanced as reporting guidelines are drafted.
Christenhusz et al. (2013). Eur. J. Hum. Genet. 21, 248–255.ta, GA 30322, USA
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Facio et al. (2013). Eur. J. Hum. Genet. 21, 261–265.
Clayton et al. (2013). Genet. Med. Published online February
28, 2013. http://dx.doi.org/10.1038/gim.2013.7.
A Middling View of the Genome
Although karyotyping gives us a chance to look at the
structure of the genome as a whole, its resolution is
limited to the detection of large structural and copy-num-
ber changes. We can achieve single-base-pair resolution
when we sequence genomes, but this still leaves an
intervening size gap within which structural variation is
not easily detected. Marie et al. developed a laboratory-
in-a-chip design that allowed them to observe the basic
genome structure of DNA molecules at ~1 kb resolution
over a length of ~ 2 Mb. As with karyotyping, this tech-
nique uses the intercalation of dyes to resolve light-dark
banding patterns representing the underlying GC content
of the sequence, albeit at a much higher resolution than a
karyotype. The chip design makes it possible to recover
the DNA and sequence it in order to link the structural
information with the DNA sequence so that one can
examine the identical stretch of DNA at different levels
of resolution. This technique increases the ability to
detect structural variation in the intermediate size
range, and the approach inherently generates haplotype-
phased data.478 The American Journal of Human Genetics 92, 477–478, April 4, 2Marie et al. (2013).Proc.Natl.Acad. Sci.USA.Publishedonline
March 11, 2013. http://dx.doi.org/10.1073/pnas.1214570110.
Folic-Acid Supplementation and Risk of Autism
For a few years, people have speculated on the correlation
between maternal folic-acid supplementation and risk of
autism in children. Some expect the correlation to be
negative, and some expect it to be positive, but data have
not come down firmly on either side. One of the largest
studies examining this association has recently been pub-
lished, and in it the authors report a reduced risk of autism
in the children of mothers who took folic-acid supple-
ments between the 4 weeks prior to pregnancy and the
8 weeks after the start of pregnancy. This prospective,
population-based Norwegian cohort included more than
85,000 children and yielded an adjusted odds ratio for
autism in children of folic-acid users of 0.61. At the same
time, no association was detected between maternal
consumption of fish-oil supplements and risk of autism,
which makes it less plausible that the link between autism
risk and folic acid is really due to the fact that more health-
conscious mothers are less likely to have children with
autism. Although neural-tube defects were the primary
target of folic-acid supplementation, reducing the risk of
autism is an added bonus.
Sure´n et al. (2013). JAMA 309, 570–577.This Month in Our Sister JournalNext-Generation Methods Get Corny
Although the maize genome is somewhat smaller than the
human genome, genotyping it is in some ways more com-
plex because it has ten times more nucleotide diversity and
many repetitive sequences as a result of transposon-
mediated rearrangements. To make the best use of next-
generation genotyping methods in maize, researchers
have advocated various strategies, including one in which
methylation-sensitive restriction enzymes are used for
preparing DNA prior to sequencing by synthesis (PLoS
One [2011] 6, e19379). Because the enzymes chosen cutretrotransposons infrequently, low-copy regions of the
genome—the ones of most interest—are more highly rep-
resented in the DNA to be genotyped. In theory, this
should provide a straightforward, inexpensive way to
genotype maize. Beissinger et al. recently assessed the use
of this approach, particularly in terms of the distribution
of sequence reads, and used these data to estimate the
coverage needed for certain types of studies, such as those
mapping quantitative trait loci.
Beissinger et al. (2013). Genetics. Published online February
14, 2013. http://dx.doi.org/10.1534/genetics.112.147710.013
